Background: Allergen immunotherapy (AIT) is effective in patient with local allergic rhinitis (LAR). However, AIT may not always achieve the optimal treatment effect. Objective: To present short study with clinical cases of LAR combined therapy with sublingual immunotherapy (SLIT) and omalizumab in patients with house dust mite (HDM) allergy and compared it to therapy with omalizumab alone. Methods: Patients with severe LAR and hypersensitivity to HDMs were included. SLIT for HDMs was launched in a perennial protocol using SQ-HDM SLIT tablets with omalizumab. The total rhinitis symptom score (TRSS), total medication score (TMS) and combined total score (CTS) were assessed after one year. Results: After 12 months, significant improvements in all analyzed parameters in the patients on SLIT+ omalizumab therapy were observed: a reduction in the TRSS from 1.21 ± 0.33 to 0.6 ± 0.28 (p
CITATION STYLE
Bozek, A., Kozłowska, R., Misiołek, M., Ścierski, W., & Gawlik, R. (2022). Omalizumab added to allergen immunotherapy increased the effect of therapy in patients with severe local allergic rhinitis. Human Vaccines and Immunotherapeutics, 18(6). https://doi.org/10.1080/21645515.2022.2097818
Mendeley helps you to discover research relevant for your work.